Stockreport

CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com
PDF -  Reductions in liver fat were minimal and not significant compared to placebo-  Reductions in markers of liver injury were robust and clinically meaningful-  Seladelpa [Read more]